Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T16:10:54.341Z.
Calculation as of: 2026-10-06T16:10:54.341Z.
Quote observation: 2026-10-06T16:10:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6a2f90c369cc2bba861e7882df5fb589e6a534c6c6a3ec3aca589af2a274c9b5
PEG RATIO
N/A
Anteris Technologies Global Corp.
Market Cap
$689.73M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$717.44M
PEG Ratio
1.00
TTM Avg
1.06
3Y Avg
1.06
5Y Avg
1.06
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Anteris Technologies Global Corp. (AVR) | $689.73M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $680.31M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $681.58M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $670.70M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $669.77M | N/A | N/A | N/A | N/A |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $714.33M | N/A | N/A | N/A | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $717.44M | 1.00 | 1.06 | 1.06 | 1.06 |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.59M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $720.94M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $648.75M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
